FY2025 Earnings Estimate for NBIX Issued By Leerink Partnrs

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Equities research analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for Neurocrine Biosciences in a note issued to investors on Monday, May 5th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings of $4.25 per share for the year, down from their previous forecast of $4.50. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share. Leerink Partnrs also issued estimates for Neurocrine Biosciences' FY2028 earnings at $10.80 EPS and FY2029 earnings at $8.75 EPS.

Other analysts have also issued research reports about the company. William Blair reissued an "outperform" rating on shares of Neurocrine Biosciences in a report on Friday, February 7th. Morgan Stanley reissued an "overweight" rating and set a $150.00 price target (down previously from $185.00) on shares of Neurocrine Biosciences in a report on Friday, March 7th. Guggenheim boosted their price objective on Neurocrine Biosciences from $155.00 to $165.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. Canaccord Genuity Group boosted their price objective on Neurocrine Biosciences from $158.00 to $160.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. Finally, StockNews.com downgraded Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a research report on Thursday, March 20th. Three equities research analysts have rated the stock with a hold rating and twenty have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $162.00.

Neurocrine Biosciences Stock Down 1.9%

NASDAQ:NBIX traded down $2.32 during mid-day trading on Thursday, hitting $118.11. 622,444 shares of the company traded hands, compared to its average volume of 1,116,013. The stock's fifty day moving average price is $106.36 and its 200-day moving average price is $121.93. Neurocrine Biosciences has a one year low of $84.23 and a one year high of $157.98. The firm has a market cap of $11.69 billion, a price-to-earnings ratio of 35.90, a price-to-earnings-growth ratio of 0.77 and a beta of 0.26.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. The company had revenue of $572.60 million for the quarter, compared to the consensus estimate of $587.06 million. During the same period in the prior year, the firm posted $1.20 EPS. The business's revenue for the quarter was up 11.1% on a year-over-year basis.

Neurocrine Biosciences declared that its board has approved a share repurchase plan on Friday, February 21st that allows the company to buyback $500.00 million in outstanding shares. This buyback authorization allows the company to reacquire up to 4.2% of its shares through open market purchases. Shares buyback plans are typically an indication that the company's board believes its stock is undervalued.

Insiders Place Their Bets

In other Neurocrine Biosciences news, CFO Matt Abernethy sold 2,558 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $116.86, for a total transaction of $298,927.88. Following the sale, the chief financial officer now directly owns 34,775 shares of the company's stock, valued at $4,063,806.50. The trade was a 6.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Julie Cooke sold 1,551 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $116.78, for a total value of $181,125.78. Following the sale, the insider now directly owns 19,544 shares in the company, valued at $2,282,348.32. The trade was a 7.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 39,953 shares of company stock valued at $4,467,990 over the last ninety days. 4.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. OneDigital Investment Advisors LLC grew its stake in shares of Neurocrine Biosciences by 2.1% during the fourth quarter. OneDigital Investment Advisors LLC now owns 4,215 shares of the company's stock valued at $575,000 after buying an additional 87 shares during the last quarter. HighPoint Advisor Group LLC grew its stake in shares of Neurocrine Biosciences by 4.1% during the fourth quarter. HighPoint Advisor Group LLC now owns 2,446 shares of the company's stock valued at $334,000 after buying an additional 96 shares during the last quarter. Huntington National Bank grew its stake in shares of Neurocrine Biosciences by 73.5% during the fourth quarter. Huntington National Bank now owns 229 shares of the company's stock valued at $31,000 after buying an additional 97 shares during the last quarter. Louisiana State Employees Retirement System grew its stake in shares of Neurocrine Biosciences by 0.4% during the fourth quarter. Louisiana State Employees Retirement System now owns 28,100 shares of the company's stock valued at $3,836,000 after buying an additional 100 shares during the last quarter. Finally, Utah Retirement Systems grew its stake in shares of Neurocrine Biosciences by 0.6% during the fourth quarter. Utah Retirement Systems now owns 16,583 shares of the company's stock valued at $2,264,000 after buying an additional 100 shares during the last quarter. Institutional investors own 92.59% of the company's stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.